KYVERNA THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX

NEW ORLEANS, La.--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NasdaqGS: KYTX), if they purchased the Company’s shares pursuant and/or traceable to the Company’s registration statement issued in connection with its February 2024 initial public offering (“IPO”). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased shares of Kyverna as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([e-mail]), or visit http://ksfcounsel.com/cases/nasdaqgs-kytx/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by February 7, 2025.

About the Lawsuit

Kyverna and certain of its executives and others are charged with failing to disclose material information in its IPO Registration Statement and Prospectus (collectively, the “Offering Documents”), violating federal securities laws.

According to the Complaint, the Company’s Offering Documents used to effectuate its IPO misstated and/or omitted facts concerning the results of the Company’s ongoing evaluation of its lead product candidate, KYV-101, in clinical trials. Specifically, the Company touted patient “improvement” in certain indicators while failing to disclose adverse data regarding one of the trials, which adverse data was known to the Company at the time of the IPO. When these true facts emerged after the Offering, the Company’s shares fell sharply, severely harming investors.

The case is Rondini v. Kyverna Therapeutics, Inc., et al., No. 24-cv-08869.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Chicago, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.